| Project/Area Number |
21591012
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所) (2011)
Miyagi Cancer Center Research Institute (2009-2010) |
|---|
Principal Investigator |
MAEMONDO Makoto 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員 (40344676)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HAGIWARA Kouichi 埼玉県立医科大学, 医学部, 教授 (00240705)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 非小細胞肺癌 / EGFR遺伝子変異 / 全ゲノムSNP解析 / 癌 / 遺伝子 |
|---|
| Research Abstract |
Lung cancer is a major cause of cancer death, and one of the most resistant cancers to treatment. Several mutations in the lung tumor were found in female, non-smoker patients with adenocarcinoma. These mutations were associated with not only oncogenicity but the target of therapy. Gefitinib is an orally administered tyrosine kinase inhibitor(TKI) of EGFR that was approved in Japan for the first time in the world. This drug has substantial role on treatment with non-small cell lung cancer patients who have characteristics that include female, never smoker, and adenocarcinoma histology. The response of treatment with gefitinib was found strongly correlated with both these patient characteristics and EGFR mutations. In addition, it was reported that there are more frequent EGFR mutations in Asian patients than in Westerners. On the hypothesis of that there are some genes associated with this ethnic difference in incidence of mutation, we conducted the study to identify these associated genes by the analysis of SNP through the whole genome with Gene chip assay.
Result : We collected blood samples from 64 patients with EGFR mutation and extracted DNA and analyzed whole genome SNP with SNP Array 6.0 which defined SNPs in more than 900, 000 sites. We found two sites associated with EGFR activating mutation with this method. We are planning to conduct re-examination with other sample set.
|
